Search: onr:"swepub:oai:DiVA.org:kau-96400" >
Cancer Drugs Reimbu...
Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life : Do Follow-Up Studies Confirm Patient Benefits?
-
- Chauca Strand, Gabriella, 1995 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine
-
- Johansson, Naimi, 1988- (author)
- Gothenburg University,Göteborgs universitet,Örebro universitet,Institutionen för hälsovetenskaper,Region Örebro län,School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden; Faculty of Medicine and Health, University Health Care Research Center, Örebro University, Örebro, Sweden,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine
-
- Jakobsson, Niklas, Professor, 1981- (author)
- Karlstads universitet,Handelshögskolan (from 2013),Karlstad Business School, Faculty of Arts and Social Sciences, Karlstads Business School, Karlstad University, Karlstad, Sweden
-
show more...
-
- Bonander, Carl, 1988- (author)
- Gothenburg University,Göteborgs universitet,Karlstads universitet,Centrum för forskning om samhällsrisker, CSR (från 2020),School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden; Centre for Societal Risk Management, Faculty of Arts and Social Sciences, Karlstad University, Karlstad, Sweden,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine
-
- Svensson, Mikael, 1980 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine
-
show less...
-
(creator_code:org_t)
- Springer, 2023
- 2023
- English.
-
In: Clinical drug investigation. - : Springer. - 1173-2563 .- 1179-1918. ; 43:8, s. 621-633
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://kau.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://gup.ub.gu.se...
-
show less...
Abstract
Subject headings
Close
- Background and ObjectiveCancer drug costs have increased considerably within healthcare systems, but many drugs lack quality-of-life (QoL) and overall survival (OS) data at the time of reimbursement approval. This study aimed to review the extent of subsequent literature documenting improvements in OS and QoL for cancer drug indications where no such evidence existed at the time of reimbursement approval.MethodsDrug indications with claims of added therapeutical value but a lack of evidence on OS and QoL that were reimbursed between 2010 and 2020 in Sweden were included for review. Searches were conducted in PubMed and ClinicalTrial.gov for randomized controlled trials examining OS and QoL.ResultsOf the 22 included drug indications, seven were found to have at least one trial with conclusive evidence of improvements in OS or QoL after a mean follow-up of 6.6 years. The remaining 15 drug indications either lacked subsequent randomized controlled trial data on OS or QoL (n = 6) or showed no statistically significant improvements (n = 9). Only one drug demonstrated evidence of improvement in both OS and QoL for its indication.ConclusionsA considerable share of reimbursed cancer drug indications continue to lack evidence of improvement in both OS and QoL. With limited healthcare resources and an increasing cancer burden, third-party payers have strong incentives to require additional post-reimbursement data to confirm any improvements in OS and QoL.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
Keyword
- renal-cell carcinoma
- european medicines agency
- early breast-cancer
- clinical benefit
- lung-cancer
- phase-III
- end-points
- open-label
- everolimus
- outcomes
- Economics
- Nationalekonomi
- Humans
- Antineoplastic Agents
- therapeutic use
- Follow-Up Studies
- Neoplasms
- drug therapy
- Quality of Life
- Sweden
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database